Switch theme
Sign up to access all valuation multiples
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.
2005
n/a
Last FY Revenue $10.9M
Last FY EBITDA -$2.9M
$345M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Hyundai Bioscience achieved revenue of $10.9M and an EBITDA of -$2.9M.
Hyundai Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hyundai Bioscience valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $10.9M | XXX | XXX | XXX |
| Gross Profit | XXX | $8.6M | XXX | XXX | XXX |
| Gross Margin | XXX | 79% | XXX | XXX | XXX |
| EBITDA | XXX | -$2.9M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -26% | XXX | XXX | XXX |
| EBIT | XXX | $0.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | 5% | XXX | XXX | XXX |
| Net Profit | XXX | -$5.0M | XXX | XXX | XXX |
| Net Margin | XXX | -46% | XXX | XXX | XXX |
| Net Debt | XXX | $16.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hyundai Bioscience's stock price is KRW 11060 (or $8).
Hyundai Bioscience has current market cap of KRW 531B (or $386M), and EV of KRW 475B (or $345M).
See Hyundai Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $345M | $386M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hyundai Bioscience has market cap of $386M and EV of $345M.
Hyundai Bioscience's trades at 31.6x EV/Revenue multiple, and -119.3x EV/EBITDA.
Equity research analysts estimate Hyundai Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hyundai Bioscience's P/E ratio is not available.
See valuation multiples for Hyundai Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $386M | XXX | $386M | XXX | XXX | XXX |
| EV (current) | $345M | XXX | $345M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 31.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -119.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 600.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -76.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 5432.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHyundai Bioscience's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Hyundai Bioscience's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hyundai Bioscience's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hyundai Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -26% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hyundai Bioscience acquired XXX companies to date.
Last acquisition by Hyundai Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Hyundai Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hyundai Bioscience founded? | Hyundai Bioscience was founded in 2005. |
| Where is Hyundai Bioscience headquartered? | Hyundai Bioscience is headquartered in South Korea. |
| Who is the CEO of Hyundai Bioscience? | Hyundai Bioscience's CEO is Mr. Sang-gi Oh. |
| Is Hyundai Bioscience publicy listed? | Yes, Hyundai Bioscience is a public company listed on KRX. |
| What is the stock symbol of Hyundai Bioscience? | Hyundai Bioscience trades under 048410 ticker. |
| When did Hyundai Bioscience go public? | Hyundai Bioscience went public in 2002. |
| Who are competitors of Hyundai Bioscience? | Similar companies to Hyundai Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Hyundai Bioscience? | Hyundai Bioscience's current market cap is $386M |
| Is Hyundai Bioscience profitable? | Yes, Hyundai Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
